{"gene":"CDC73","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":2005,"finding":"Parafibromin (CDC73) is a component of a human PAF1 complex that includes homologs of Leo1, Paf1, and Ctr9, and associates with non-phosphorylated and Ser2/Ser5-phosphorylated forms of the RNA polymerase II large subunit. Immunofluorescence confirmed nuclear localization. Cotransfection data suggested parafibromin can interact with a histone methyltransferase complex that methylates histone H3 on lysine 4. Some tumor-derived mutant forms of parafibromin lack association with hPaf1 complex members and the histone methyltransferase complex.","method":"Protein purification, mass spectrometry identification of associated proteins, co-immunoprecipitation, immunofluorescence, cotransfection assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal purification and Co-IP with multiple orthogonal methods; replicated by independent lab (PMID:15923622)","pmids":["15632063"],"is_preprint":false},{"year":2005,"finding":"Parafibromin physically interacts with human orthologs of yeast Paf1 complex components (PAF1, LEO1, CTR9) involved in transcription elongation and 3' end processing, and associates with Ser5- and Ser2-phosphorylated forms of RNA polymerase II large subunit. These interactions depend on a C-terminal domain of parafibromin deleted in ~80% of clinically relevant mutations. RNAi-induced downregulation of parafibromin promotes entry into S phase.","method":"Co-immunoprecipitation, RNAi knockdown, cell cycle analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, domain mapping, functional KD phenotype; independently replicated (PMID:15632063)","pmids":["15923622"],"is_preprint":false},{"year":2006,"finding":"Drosophila Hyrax and its human ortholog parafibromin, components of the PAF1 complex, are required for nuclear transduction of the Wnt/Wg signal and bind directly to the C-terminal region of beta-catenin/Armadillo. The transactivation potential of Parafibromin/Hyrax depends on recruitment of Pygopus to beta-catenin/Armadillo, establishing a molecular mechanism in which the nuclear Wnt signaling complex directly engages the PAF1 complex to control transcriptional initiation and elongation by RNA Pol II.","method":"Genetic epistasis in Drosophila, direct binding assay (pulldown), transcriptional reporter assays, RNAi","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic epistasis combined with direct binding and transcriptional assays; landmark study with multiple orthogonal methods","pmids":["16630820"],"is_preprint":false},{"year":2005,"finding":"Parafibromin overexpression (wild-type but not Leu64Pro missense mutant) inhibits cell proliferation and blocks expression of cyclin D1. Subcellular fractionation and confocal microscopy demonstrated parafibromin expression in both cytoplasmic and nuclear compartments of normal parathyroid gland.","method":"Transient overexpression, proliferation assay, cyclin D1 expression analysis, subcellular fractionation, laser confocal microscopy","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — clean overexpression with mutant control and defined readout, single lab","pmids":["15580289"],"is_preprint":false},{"year":2006,"finding":"Parafibromin has a functional monopartite nuclear localization signal (NLS) at residues 136-139 (KKXR motif), identified by systematic deletion/mutation of predicted NLS sequences; mutation of this NLS abolishes nuclear localization. Over 60% of all parafibromin mutations lead to loss of this NLS.","method":"Site-directed mutagenesis, GFP-tagged constructs, confocal fluorescence microscopy, Western blot of nuclear/cytoplasmic fractions in COS-7 and HEK293 cells","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with multiple NLS variants and direct localization readout; consistent with independent NLS mapping study (PMID:16116486)","pmids":["16964291"],"is_preprint":false},{"year":2005,"finding":"Parafibromin contains a functional bipartite nuclear localization signal (NLS) at residues 125-139 (KRAADEVLAEAKKPR). The C-terminal arm of this bipartite NLS plays the primary role in nuclear localization. Specific HRPT2 mutations that truncate parafibromin upstream of or within this NLS disrupt nuclear localization.","method":"EGFP-tagged wild-type and mutant parafibromin expression, confocal microscopy","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with mutagenesis, single lab","pmids":["16116486"],"is_preprint":false},{"year":2007,"finding":"Nuclear localization of parafibromin enhances its proapoptotic function. NLS-mutant parafibromin is significantly impaired in association with endogenous Paf1 and Leo1. Overexpression of wild-type but not NLS-mutant parafibromin induces apoptosis. RNAi knockdown of endogenous parafibromin inhibits basal apoptosis and apoptosis resulting from DNA damage (camptothecin treatment).","method":"Site-directed mutagenesis, NLS mutation, co-immunoprecipitation, RNAi, apoptosis assays","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (mutagenesis, Co-IP, RNAi) in single lab","pmids":["17314275"],"is_preprint":false},{"year":2008,"finding":"Parafibromin tumor suppressor protein inhibits cell proliferation and represses the c-myc proto-oncogene. RNAi knockdown of parafibromin or Paf1 stimulates cell proliferation and increases c-myc protein levels via both c-myc protein stabilization and activation of the c-myc promoter. Chromatin immunoprecipitation demonstrates occupancy of the c-myc promoter by parafibromin and other PAF1 complex subunits. Knockdown of c-myc blocks the proliferative effect of parafibromin RNAi.","method":"RNAi, cell proliferation assay, Western blot, chromatin immunoprecipitation (ChIP), epistasis by double knockdown","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (RNAi, ChIP, epistasis) in single lab establishing direct promoter occupancy and pathway placement","pmids":["18987311"],"is_preprint":false},{"year":2009,"finding":"Parafibromin interacts with the histone methyltransferase SUV39H1 through its central region (residues 128-227) and functions as a transcriptional repressor. Parafibromin associates with the promoter and coding regions of cyclin D1 and is required for recruitment of SUV39H1 and induction of H3 K9 methylation (but not H3 K4 methylation) at the cyclin D1 locus, leading to repression.","method":"Co-immunoprecipitation, deletion mapping, ChIP, RNAi","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with domain mapping, ChIP, and RNAi epistasis in single lab","pmids":["19906718"],"is_preprint":false},{"year":2009,"finding":"Cdc73/parafibromin physically associates with the cleavage and polyadenylation specificity factor (CPSF) and cleavage stimulation factor (CstF) complexes. Immunodepletion of Cdc73-CPSF-CstF complex abolishes 3' mRNA processing in vitro. CDC73 siRNA depletion results in decreased INTS6 mRNA and decreased association of CPSF and CstF subunits with the INTS6 locus.","method":"Co-immunoprecipitation, in vitro mRNA processing assay with immunodepletion, microarray analysis, ChIP","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro reconstitution/immunodepletion assay plus ChIP, multiple orthogonal methods in single lab","pmids":["19136632"],"is_preprint":false},{"year":2011,"finding":"SHP2 tyrosine phosphatase dephosphorylates parafibromin/Cdc73 on tyrosine residues. Upon dephosphorylation by SHP2, parafibromin acquires the ability to stably bind beta-catenin. The parafibromin/beta-catenin interaction overrides parafibromin/SUV39H1-mediated transrepression and induces expression of Wnt target genes including cyclin D1 and c-myc. Thus SHP2 governs the switch between parafibromin's tumor-suppressive and oncogenic functions.","method":"In vitro phosphatase assay, co-immunoprecipitation, reporter gene assays, phosphorylation-state mapping","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro phosphatase assay plus Co-IP and functional reporter assays demonstrating mechanistic switch; multiple orthogonal methods","pmids":["21726809"],"is_preprint":false},{"year":2011,"finding":"CDC73 interacts with ring finger proteins RNF20 and RNF40 (which form the E3 ubiquitin ligase for H2B-K120 monoubiquitination), identified by yeast two-hybrid. RNF20 and RNF40 bind to discrete but closely located residues on CDC73. Loss of nuclear CDC73 (by siRNA or tumor mutations) significantly reduces monoubiquitinated H2B-K120. H3-K4me3 was not changed by CDC73 loss, indicating these modifications are not always tightly linked.","method":"Yeast two-hybrid, co-immunoprecipitation, RNAi knockdown, analysis of H2B-K120 monoubiquitination by Western blot, immunohistochemistry in CDC73-mutant tumors","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid confirmed by Co-IP, with functional histone modification readout in vitro and in vivo tumor specimens","pmids":["22021426"],"is_preprint":false},{"year":2008,"finding":"Parafibromin (in the PAF complex) directly regulates genes involved in cell growth and survival including H19, Igf1, Igf2, Igfbp4, Hmga1, Hmga2, and Hmgcs2, as demonstrated by cDNA microarray, RT-PCR, and ChIP in parafibromin-null mouse embryonic fibroblasts. Hrpt2-/- mice are embryonic lethal by E6.5 and conditional deletion in adults causes cachexia and death within 20 days. Hrpt2-/- MEFs undergo apoptosis.","method":"Conventional and conditional knockout mice, MEF culture, cDNA microarray, ChIP, RT-PCR, apoptosis assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple genetic KO models plus ChIP and transcriptomics establishing direct gene targets; rigorous in vivo and in vitro validation","pmids":["18212049"],"is_preprint":false},{"year":2010,"finding":"Parafibromin regulates 3' processing of replication-dependent histone mRNA. Downregulation of parafibromin by RNAi or tumor-associated mutations leads to uncleaved histone mRNA with polyadenylated tails, revealing a posttranscriptional role for parafibromin.","method":"RNAi knockdown, in vivo mutation analysis, histone mRNA 3' processing assay","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional in vitro and in vivo RNAi studies with specific mRNA processing readout, single lab","pmids":["19908240"],"is_preprint":false},{"year":2008,"finding":"Parafibromin interacts with muscle alpha-actinins (actinin-2 and actinin-3) but not non-muscle alpha-actinins (actinin-1 and actinin-4) through its N-terminal region. Parafibromin can bundle/cross-link actin filaments in actin sedimentation assays. In differentiated myotubes, parafibromin co-localizes with actinins in the cytoplasmic compartment, whereas in undifferentiated myoblasts it is predominantly nuclear.","method":"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, actin sedimentation assay, confocal microscopy","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid confirmed by GST pulldown and Co-IP, functional actin bundling assay, localization by microscopy; single lab","pmids":["18687124"],"is_preprint":false},{"year":2006,"finding":"Parafibromin inhibits cancer cell colony formation and proliferation and causes G1 phase cell cycle arrest when overexpressed. HPT-JT syndrome-derived mutations in HRPT2 behave in a dominant-negative manner by abolishing the ability of parafibromin to suppress cell proliferation.","method":"Colony formation assay, cell proliferation assay, cell cycle analysis (flow cytometry), dominant-negative overexpression of mutant constructs","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — overexpression with multiple mutants and defined cell cycle readout, single lab","pmids":["16989776"],"is_preprint":false},{"year":2009,"finding":"Parafibromin/Hyrax directly binds Region 1 (the Su(fu) interaction domain) in the N-terminus of all three Gli proteins and Ci in Drosophila, forming complexes with Gli1, Gli2, and Gli3. RNAi knockdown of Hyrax impairs Hedgehog pathway activity in Drosophila cells. RNAi knockdown of Parafibromin in mammalian cells diminishes transcriptional activity of Gli1 and Gli2.","method":"Co-immunoprecipitation, RNAi in Drosophila cells and mammalian cells, Hh reporter assay, genetic overexpression in vivo","journal":"Mechanisms of development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional RNAi in two model systems, single lab","pmids":["19368795"],"is_preprint":false},{"year":2012,"finding":"The Cdc73 subunit of the yeast Paf1 complex contains a C-terminal Ras-like domain (C-domain). The crystal structure of this domain reveals similarity to the Ras family of small GTPases with a large flat conserved surface. Deletion of the C-domain causes elongation defects and reduced chromatin association for multiple Paf1 complex subunits without loss of complex integrity. Simultaneous mutation of the C-domain and Rtf1 causes loss of H3K36 trimethylation.","method":"Crystal structure determination, deletion analysis, yeast genetics, chromatin immunoprecipitation","journal":"Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure combined with genetic functional validation and ChIP; multiple orthogonal methods in single rigorous study","pmids":["22318720"],"is_preprint":false},{"year":2014,"finding":"Cytoplasmic parafibromin/hCdc73 targets and destabilizes p53 mRNA to control p53-mediated apoptosis. hCdc73 associates with mature p53 mRNA in the cytoplasm and facilitates its degradation by physically interacting with eEF1Bγ and hSki8; these interactions are required for binding and destabilizing p53 mRNA. A cancer-derived hCdc73(K34Q) mutant showed enhanced association with p53 mRNA, resulting in reduced p53 expression and enhanced cell proliferation.","method":"RNA immunoprecipitation, co-immunoprecipitation, mRNA stability assay, RNAi, overexpression of mutant constructs","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-IP and Co-IP with functional mutant analysis, single lab","pmids":["25388829"],"is_preprint":false},{"year":2015,"finding":"CDC73/Parafibromin is required for homologous recombination repair of ionizing radiation-induced DNA damage. CDC73 interacts with components of the SCF/Cullin and INO80/NuA4 chromatin-remodeling complexes to promote histone ubiquitination at sites of DNA damage, facilitating local chromatin decondensation for DNA repair. This function is related to but independent of its role in transcriptional elongation.","method":"Genome-wide siRNA screen with RAD51 foci readout, validation by independent siRNAs, recombination repair activity assay, RPA foci formation assay, co-immunoprecipitation","journal":"Cell discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide screen with secondary validation assays and Co-IP, single lab","pmids":["27462432"],"is_preprint":false},{"year":2016,"finding":"Dephosphorylated parafibromin competitively interacts with both beta-catenin and Gli1, potentiating Wnt and Hedgehog target gene transactivation in a mutually exclusive manner. Parafibromin also binds the Notch intracellular domain (NICD), enabling concerted activation of Wnt- and Notch-target genes. Tyrosine dephosphorylation by SHP2 phosphatase potentiates, while tyrosine phosphorylation by PTK6 kinase attenuates, the transcriptional platform function of parafibromin. Acute loss of parafibromin in mice disorganizes the normal epithelial architecture of the intestine.","method":"Co-immunoprecipitation, reporter assays, competitive binding assay, conditional knockout mice, intestinal phenotype analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple binding assays, reporter assays, and in vivo genetic model with defined phenotype in single rigorous study","pmids":["27650679"],"is_preprint":false},{"year":2018,"finding":"YAP and TAZ transcriptional co-activator functions are inversely regulated by the tyrosine phosphorylation status of parafibromin. TAZ and Wnt effector beta-catenin interact cooperatively with tyrosine-dephosphorylated parafibromin, synergistically stimulating co-activator functions. YAP is selectively activated through binding with tyrosine-phosphorylated parafibromin, which does not interact with beta-catenin. Thus YAP and TAZ exert redundant and non-redundant functions through mutually exclusive interaction with parafibromin regulated by kinase/phosphatase balance.","method":"Co-immunoprecipitation, reporter assays, phosphorylation-state analysis, mutant overexpression","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple Co-IPs and reporter assays establishing mechanistic switch, single lab","pmids":["30227954"],"is_preprint":false},{"year":2015,"finding":"Parafibromin is a component of IFN-γ-triggered signaling pathways. Parafibromin interacts with JAK1 and JAK2, promotes JAK1-JAK2 and JAK1/2-STAT1 interactions, and promotes tyrosine phosphorylation of STAT1 at Tyr701 after IFN-γ stimulation. Overexpression of parafibromin enhanced IFN-γ-triggered STAT1 phosphorylation and downstream gene expression; knockdown had opposite effects.","method":"Co-immunoprecipitation, overexpression, RNAi knockdown, STAT1 phosphorylation assay, antiviral response assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with functional overexpression and knockdown readout, single lab","pmids":["26232434"],"is_preprint":false},{"year":2022,"finding":"UBR5 E3 ubiquitin ligase targets CDC73 for proteasomal degradation by polyubiquitination at Lys243, Lys247, and Lys257. This ubiquitination depends on the non-phosphorylated state of CDC73 at Ser465. CDC73 degradation by UBR5 regulates beta-catenin and E-cadherin expression, tumor cell apoptosis, and CD8+ T cell infiltration in triple-negative breast cancer.","method":"Co-immunoprecipitation, ubiquitination assay, mutagenesis of ubiquitin acceptor sites and phosphorylation site, in vitro degradation assay","journal":"Cell death and disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination mapping with site mutagenesis and functional readout, single lab","pmids":["35551175"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of the human CDC73 N-terminal domain (residues 1-111) was determined at 1.02 Å resolution, revealing a novel protein fold with an extended hydrophobic groove. Most pathogenic HPT-JT-associated missense mutations are located in the region encoding CDC73-NTD and disrupt the folding of the hydrophobic core, while others (e.g., K34Q) reduce thermostability.","method":"Limited proteolysis, X-ray crystallography, biochemical stability assays, mutant analysis","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure at high resolution with biochemical validation of missense mutations; single lab","pmids":["29142233"],"is_preprint":false},{"year":2010,"finding":"The L95P missense mutant parafibromin is markedly deficient in nucleolar localization (disrupting a putative nucleolar localization signal immediately upstream of L95P), while retaining ability to assemble with endogenous PAF1 complex components by co-immunoprecipitation. Transfection of L95P parafibromin enhances cell cycle progression and cell survival, acting as a dominant-negative inhibitor of endogenous parafibromin.","method":"Subcellular localization by confocal microscopy, co-immunoprecipitation, cell cycle and cell survival assays with dominant-negative mutant","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — direct localization and Co-IP with functional dominant-negative readout, single lab","pmids":["20304979"],"is_preprint":false},{"year":2015,"finding":"LEOPARD syndrome-associated SHP2 mutants (Y279C, T468M, Q506P, Q510E) exhibit substantially reduced phosphatase activity toward tyrosine-phosphorylated parafibromin compared to wild-type SHP2, as demonstrated in a direct in vitro phosphatase assay using parafibromin as substrate. Each LS-associated mutant displayed a differential degree of decrease in phosphatase activity.","method":"In vitro phosphatase assay with tyrosine-phosphorylated parafibromin as substrate","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro assay with multiple mutants, single lab, single method","pmids":["26742426"],"is_preprint":false},{"year":2018,"finding":"In S. cerevisiae, Cdc73 directly interacts with two components of the RNA Pol II elongation complex: the elongation factor Spt6 and the largest subunit of Pol II, both interactions requiring the tandem SH2 domain of Spt6. Rapid depletion of Spt6 dissociates Paf1 from chromatin and alters Paf1C-dependent histone modifications genome-wide. Cdc73 and Spt6 can interact in vitro.","method":"Site-specific protein cross-linking in yeast, in vitro binding assay, rapid depletion/ChIP, genome-wide histone modification analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vivo cross-linking, in vitro binding, and genome-wide ChIP with rapid depletion; multiple orthogonal methods","pmids":["36928138"],"is_preprint":false},{"year":2018,"finding":"In S. cerevisiae, Cdc73 suppresses genome instability by mediating telomere homeostasis. Loss of Cdc73 increases gross chromosomal rearrangement (GCR) rates. A central 105 amino acid region of Cdc73 is necessary and sufficient for suppressing GCR defects; this region mediates binding of Cdc73 to the Paf1 complex through Ctr9 and is required for nuclear localization. Synergistic increases in GCRs occur when cdc73Δ is combined with tel1Δ or yku80Δ, and telomere length defects are enhanced.","method":"GCR rate assay, genome sequencing of GCRs, deletion mapping of Cdc73, telomere length analysis, genetic epistasis","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis, functional domain mapping, and telomere analysis; multiple orthogonal methods in yeast model","pmids":["29320491"],"is_preprint":false},{"year":2012,"finding":"MiR-155 negatively regulates CDC73 expression at the post-transcriptional level by targeting CDC73 mRNA. Ectopic expression of miR-155 in HEK293 cells reduced CDC73 levels, enhanced cell viability, and decreased apoptosis. Delivery of miR-155 antagomir to KB cells restored CDC73 levels, decreased cell viability, and increased apoptosis. Co-transfection of miR-155 with CDC73 (without 3'-UTR) abrogated the pro-oncogenic effect of miR-155.","method":"MiR-155 overexpression and antagomir delivery, Western blot for CDC73, cell viability and apoptosis assays, 3'-UTR-dependent expression analysis, xenograft tumor model","journal":"Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — gain/loss-of-function with epistasis rescue, in vitro and in vivo readout; single lab","pmids":["23166327"],"is_preprint":false},{"year":2013,"finding":"WT1 (Wilms tumor 1 protein) transcriptionally represses CDC73 by binding to the CDC73 promoter. ChIP and EMSA demonstrated direct WT1 binding to the CDC73 promoter. Overexpression of WT1 decreased CDC73 levels and promoted proliferation of OSCC cells. Exogenous CDC73 attenuated the pro-tumorigenic activity of WT1.","method":"ChIP, EMSA, overexpression, knockdown, proliferation/apoptosis assays, 5-azacytidine treatment","journal":"Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding demonstrated by ChIP and EMSA with functional epistasis, single lab","pmids":["24257751"],"is_preprint":false},{"year":2020,"finding":"Disruption of the C-terminal domain (CTD) of parafibromin by germline CDC73 mutations is directly associated with predisposition to parathyroid carcinoma. High-impact mutations predicted to cause conformational disruption or loss of expression of parafibromin confer a 6.6-fold higher risk of parathyroid carcinoma compared to low-impact mutations. Structural analysis revealed a conserved surface structure in the CTD that is universally disrupted by carcinoma-associated mutations.","method":"Cohort analysis of mutation carriers with Kaplan-Meier analysis, structural modeling of CTD mutations","journal":"Endocrine-related cancer","confidence":"Low","confidence_rationale":"Tier 4 / Moderate — structural inference from mutation correlation; no direct functional experiment performed","pmids":["32590342"],"is_preprint":false}],"current_model":"CDC73/parafibromin is a nuclear tumor suppressor that functions as a core subunit of the RNA Polymerase II-associated PAF1 complex, where it facilitates transcription elongation, 3' mRNA processing (via association with CPSF/CstF), and histone modifications (H3K9me via SUV39H1 and H2B-K120 monoubiquitination via RNF20/RNF40); it represses oncogenes cyclin D1 and c-myc, while its transcriptional coactivator function—particularly activation of Wnt, Hedgehog, and Notch target genes through direct binding to beta-catenin, Gli proteins, and NICD—is governed by SHP2-mediated tyrosine dephosphorylation (activating) versus PTK6-mediated tyrosine phosphorylation (inhibiting), with UBR5-dependent proteasomal degradation providing an additional layer of regulation."},"narrative":{"mechanistic_narrative":"CDC73/parafibromin is a nuclear tumor suppressor that functions as a core subunit of the human PAF1 complex (with PAF1, LEO1, and CTR9), coupling RNA polymerase II transcription elongation to histone modification and 3' mRNA processing [PMID:15632063, PMID:15923622, PMID:19136632]. Within this complex it controls transcription of genes governing proliferation and survival: it represses the oncogenes cyclin D1 and c-myc, occupying their promoters and recruiting the histone methyltransferase SUV39H1 to deposit repressive H3K9 methylation at cyclin D1 [PMID:18987311, PMID:19906718], and it interacts with the RNF20/RNF40 E3 ligase to promote H2B-K120 monoubiquitination [PMID:22021426]. CDC73 also acts as a transcriptional co-activator at developmental signaling pathways, binding directly to beta-catenin (Wnt), Gli proteins (Hedgehog), and the Notch intracellular domain to drive target-gene expression [PMID:16630820, PMID:19368795, PMID:27650679]. This dual repressor/activator output is governed by a tyrosine phosphorylation switch: SHP2-mediated dephosphorylation enables stable beta-catenin binding and an oncogenic activating program, whereas PTK6 phosphorylation attenuates it, with the phospho-state also dictating selective engagement of TAZ versus YAP [PMID:21726809, PMID:27650679, PMID:30227954]. Nuclear function depends on an N-terminal nuclear localization signal and the structured N- and C-terminal domains, regions disrupted by the majority of HPT-JT and parathyroid carcinoma-associated mutations [PMID:16964291, PMID:29142233, PMID:32590342]. Beyond transcription, CDC73 contributes to homologous recombination DNA repair through SCF/Cullin and INO80/NuA4 complexes [PMID:27462432] and exerts cytoplasmic post-transcriptional roles, including destabilization of p53 mRNA via eEF1Bgamma and hSki8 [PMID:25388829]. Germline CDC73 mutations that disrupt the C-terminal domain predispose to parathyroid carcinoma [PMID:32590342].","teleology":[{"year":2005,"claim":"Establishing that parafibromin is a bona fide subunit of the RNA Pol II-associated PAF1 complex placed an uncharacterized tumor suppressor into a defined transcriptional machinery and showed tumor mutations disrupt this association.","evidence":"Protein purification, mass spectrometry, reciprocal Co-IP and immunofluorescence in human cells; replicated with domain mapping and RNAi cell-cycle assays","pmids":["15632063","15923622"],"confidence":"High","gaps":["Whether PAF1 complex assembly is sufficient for tumor suppression not resolved","Direct enzymatic activity of CDC73 within the complex undefined"]},{"year":2006,"claim":"Identification of direct binding to beta-catenin/Armadillo defined parafibromin as a nuclear effector of Wnt signaling, recasting the PAF1 complex as a transcriptional platform engaged by developmental pathways.","evidence":"Drosophila genetic epistasis, direct pulldown, transcriptional reporter assays, RNAi","pmids":["16630820"],"confidence":"High","gaps":["How the same protein both represses and activates Wnt targets not yet reconciled at this stage"]},{"year":2005,"claim":"Mapping a functional nuclear localization signal explained why ~60% of clinical mutations cause mislocalization, linking subcellular targeting to loss of tumor-suppressor function.","evidence":"Site-directed mutagenesis of NLS variants, GFP/EGFP constructs, confocal microscopy and nuclear/cytoplasmic fractionation","pmids":["16964291","16116486"],"confidence":"High","gaps":["Import receptor mediating NLS recognition not identified","Monopartite versus bipartite NLS boundaries differ between studies"]},{"year":2008,"claim":"Knockout mouse models and direct promoter occupancy studies established CDC73 as an essential gene that directly represses c-myc and regulates growth/survival genes, defining its anti-proliferative mechanism.","evidence":"Conventional and conditional knockout mice, MEF transcriptomics, ChIP, RT-PCR, plus RNAi/ChIP/epistasis at the c-myc locus","pmids":["18212049","18987311"],"confidence":"High","gaps":["Mechanism distinguishing repressed versus activated targets not defined","Embryonic lethality limits tissue-specific dissection"]},{"year":2009,"claim":"Linking CDC73 to SUV39H1-mediated H3K9 methylation and to CPSF/CstF-dependent 3' processing extended its mechanism from elongation to chromatin repression and mRNA maturation.","evidence":"Co-IP with deletion mapping, ChIP, RNAi, and in vitro mRNA processing assays with immunodepletion","pmids":["19906718","19136632"],"confidence":"High","gaps":["Whether 3' processing and transcriptional roles are mechanistically separable unresolved","Genome-wide scope of CPSF/CstF coupling not mapped"]},{"year":2009,"claim":"Demonstration of direct Gli binding generalized parafibromin's co-activator role beyond Wnt to the Hedgehog pathway.","evidence":"Co-IP, RNAi in Drosophila and mammalian cells, Hedgehog reporter assays","pmids":["19368795"],"confidence":"Medium","gaps":["Competition between Gli and beta-catenin binding not yet examined at this stage","Structural basis of Gli interaction undefined"]},{"year":2011,"claim":"Discovery of the SHP2 tyrosine dephosphorylation switch resolved the repressor/activator paradox, showing a single post-translational signal toggles parafibromin between tumor-suppressive and oncogenic outputs.","evidence":"In vitro phosphatase assay, Co-IP, reporter assays, phosphorylation-state mapping","pmids":["21726809"],"confidence":"High","gaps":["Upstream signals controlling SHP2 activity toward parafibromin unidentified","Specific phosphotyrosine residues and counteracting kinase not yet defined here"]},{"year":2011,"claim":"Identification of RNF20/RNF40 binding connected CDC73 to H2B-K120 monoubiquitination, adding a second histone-modification arm to its chromatin function.","evidence":"Yeast two-hybrid, Co-IP, RNAi, H2B-K120ub Western blot, tumor immunohistochemistry","pmids":["22021426"],"confidence":"High","gaps":["Functional consequence of H2B ubiquitination loss for specific target genes not delineated"]},{"year":2012,"claim":"Crystallization of the yeast Cdc73 C-terminal Ras-like domain provided structural rationale for its role in elongation and chromatin association and for the clustering of clinical mutations in this region.","evidence":"Crystal structure, deletion analysis, yeast genetics, ChIP","pmids":["22318720"],"confidence":"High","gaps":["Whether the Ras-like surface binds a GTPase or other partner unknown","No nucleotide-binding activity demonstrated"]},{"year":2014,"claim":"Defining a cytoplasmic role in destabilizing p53 mRNA revealed a transcription-independent oncogenic function for CDC73 acting through RNA decay machinery.","evidence":"RNA-IP, Co-IP with eEF1Bgamma and hSki8, mRNA stability assays, RNAi, cancer mutant analysis","pmids":["25388829"],"confidence":"Medium","gaps":["Single lab; reciprocal validation of eEF1Bgamma/hSki8 RNA-decay complex limited","Signal partitioning CDC73 between nucleus and cytoplasm unclear"]},{"year":2015,"claim":"A genome-wide screen placed CDC73 in homologous recombination DNA repair, linking it to SCF/Cullin and INO80/NuA4 chromatin remodeling at damage sites independently of elongation.","evidence":"Genome-wide siRNA screen with RAD51 foci, recombination repair and RPA foci assays, Co-IP","pmids":["27462432"],"confidence":"Medium","gaps":["Direct enzymatic role at break sites not established","Interaction with INO80/NuA4 not reciprocally mapped"]},{"year":2016,"claim":"Showing competitive, mutually exclusive binding to beta-catenin, Gli1, and NICD, all tuned by SHP2/PTK6, established parafibromin as an integrating hub coordinating Wnt, Hedgehog, and Notch output, with in vivo intestinal phenotypes.","evidence":"Competitive binding and reporter assays, Co-IP, conditional knockout mice with intestinal phenotyping","pmids":["27650679"],"confidence":"High","gaps":["Quantitative rules governing pathway selection not defined","Tissue-specific kinase/phosphatase balance not mapped"]},{"year":2017,"claim":"High-resolution structure of the CDC73 N-terminal domain explained how HPT-JT missense mutations destabilize the protein, providing a structural basis for loss of function.","evidence":"Limited proteolysis, X-ray crystallography at 1.02 A, biochemical stability assays, mutant analysis","pmids":["29142233"],"confidence":"High","gaps":["Binding partner engaged by the NTD hydrophobic groove not identified"]},{"year":2018,"claim":"Extending the phospho-switch to YAP/TAZ and identifying the Spt6 elongation-factor contact (in yeast) further refined how phosphorylation state and elongation machinery shape parafibromin co-activator selectivity.","evidence":"Co-IP and reporter assays for YAP/TAZ; yeast site-specific cross-linking, in vitro binding, rapid depletion and genome-wide ChIP for Spt6","pmids":["30227954","36928138"],"confidence":"Medium","gaps":["YAP/TAZ findings single lab without in vivo confirmation","Conservation of Spt6 contact in human PAF1 complex not tested"]},{"year":2022,"claim":"Identification of UBR5-mediated, phospho-dependent polyubiquitination of CDC73 added a degradation layer controlling parafibromin levels and downstream beta-catenin/E-cadherin and immune phenotypes in breast cancer.","evidence":"Co-IP, ubiquitination assays, mutagenesis of acceptor lysines and Ser465, in vitro degradation assay","pmids":["35551175"],"confidence":"Medium","gaps":["Single lab; physiological signals triggering UBR5 targeting unknown","Interplay with SHP2/PTK6 phospho-switch not integrated"]},{"year":null,"claim":"How the competing nuclear (PAF1 elongation, repression, co-activation, DNA repair) and cytoplasmic (mRNA destabilization, actin bundling) activities of parafibromin are coordinately regulated in a cell-type-specific manner, and which functions are most relevant to tumor suppression, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model integrating phospho-switch, ubiquitination, and localization control","Functional ranking of nuclear versus cytoplasmic roles in carcinogenesis undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,7,8,16,20]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[9,18]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[8,11]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,2,20]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[14]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,4,6]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[14,18]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[25]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,7,8]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[9,13,18]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,16,20,21]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[8,11]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[31]}],"complexes":["PAF1 complex","CPSF/CstF 3' processing complex"],"partners":["PAF1","LEO1","CTR9","CTNNB1","SUV39H1","RNF20","PTPN11","PTK6"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q6P1J9","full_name":"Parafibromin","aliases":["Cell division cycle protein 73 homolog","Hyperparathyroidism 2 protein"],"length_aa":531,"mass_kda":60.6,"function":"Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Connects PAF1C with the cleavage and polyadenylation specificity factor (CPSF) complex and the cleavage stimulation factor (CSTF) complex, and with Wnt signaling. Involved in polyadenylation of mRNA precursors","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q6P1J9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/CDC73","classification":"Common Essential","n_dependent_lines":1195,"n_total_lines":1208,"dependency_fraction":0.9892384105960265},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"SSRP1","stoichiometry":4.0},{"gene":"TOP1","stoichiometry":4.0},{"gene":"CALM2","stoichiometry":0.2},{"gene":"CALM3","stoichiometry":0.2},{"gene":"CPSF6","stoichiometry":0.2},{"gene":"SNRPA","stoichiometry":0.2},{"gene":"SNRPB","stoichiometry":0.2},{"gene":"SNRPC","stoichiometry":0.2},{"gene":"SRP9","stoichiometry":0.2},{"gene":"SUPT5H","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/CDC73","total_profiled":1310},"omim":[{"mim_id":"617343","title":"HYPERPARATHYROIDISM 4; HRPT4","url":"https://www.omim.org/entry/617343"},{"mim_id":"610507","title":"LEO1 HOMOLOG, PAF1/RNA POLYMERASE II COMPLEX COMPONENT; LEO1","url":"https://www.omim.org/entry/610507"},{"mim_id":"610506","title":"PAF1 HOMOLOG, PAF1/RNA POLYMERASE II COMPLEX COMPONENT; PAF1","url":"https://www.omim.org/entry/610506"},{"mim_id":"610071","title":"HYPERPARATHYROIDISM 3; HRPT3","url":"https://www.omim.org/entry/610071"},{"mim_id":"609366","title":"CTR9 HOMOLOG, PAF1/RNA POLYMERASE II COMPLEX COMPONENT; CTR9","url":"https://www.omim.org/entry/609366"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CDC73"},"hgnc":{"alias_symbol":["parafibromin","FIHP"],"prev_symbol":["C1orf28","HRPT2","HRPT1"]},"alphafold":{"accession":"Q6P1J9","domains":[{"cath_id":"-","chopping":"3-118","consensus_level":"high","plddt":87.6978,"start":3,"end":118},{"cath_id":"3.40.50.11990","chopping":"360-525","consensus_level":"high","plddt":86.6706,"start":360,"end":525}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6P1J9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6P1J9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6P1J9-F1-predicted_aligned_error_v6.png","plddt_mean":73.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CDC73","jax_strain_url":"https://www.jax.org/strain/search?query=CDC73"},"sequence":{"accession":"Q6P1J9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6P1J9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6P1J9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6P1J9"}},"corpus_meta":[{"pmid":"12434154","id":"PMC_12434154","title":"HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.","date":"2002","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12434154","citation_count":511,"is_preprint":false},{"pmid":"14585940","id":"PMC_14585940","title":"Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.","date":"2003","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14585940","citation_count":399,"is_preprint":false},{"pmid":"16630820","id":"PMC_16630820","title":"Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16630820","citation_count":258,"is_preprint":false},{"pmid":"12960210","id":"PMC_12960210","title":"HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours.","date":"2003","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12960210","citation_count":249,"is_preprint":false},{"pmid":"15632063","id":"PMC_15632063","title":"The parafibromin tumor suppressor protein is part of a human Paf1 complex.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15632063","citation_count":230,"is_preprint":false},{"pmid":"7717405","id":"PMC_7717405","title":"Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31.","date":"1995","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7717405","citation_count":188,"is_preprint":false},{"pmid":"15531515","id":"PMC_15531515","title":"Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15531515","citation_count":172,"is_preprint":false},{"pmid":"15475453","id":"PMC_15475453","title":"Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15475453","citation_count":161,"is_preprint":false},{"pmid":"16931959","id":"PMC_16931959","title":"Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.","date":"2006","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16931959","citation_count":155,"is_preprint":false},{"pmid":"15923622","id":"PMC_15923622","title":"The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15923622","citation_count":154,"is_preprint":false},{"pmid":"20052758","id":"PMC_20052758","title":"Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20052758","citation_count":134,"is_preprint":false},{"pmid":"15580289","id":"PMC_15580289","title":"Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15580289","citation_count":122,"is_preprint":false},{"pmid":"19136632","id":"PMC_19136632","title":"The tumor suppressor Cdc73 functionally associates with CPSF and CstF 3' mRNA processing factors.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19136632","citation_count":114,"is_preprint":false},{"pmid":"14715834","id":"PMC_14715834","title":"Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/14715834","citation_count":109,"is_preprint":false},{"pmid":"17468190","id":"PMC_17468190","title":"Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?","date":"2007","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17468190","citation_count":101,"is_preprint":false},{"pmid":"23166327","id":"PMC_23166327","title":"Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23166327","citation_count":101,"is_preprint":false},{"pmid":"19017757","id":"PMC_19017757","title":"Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19017757","citation_count":96,"is_preprint":false},{"pmid":"23293331","id":"PMC_23293331","title":"Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism.","date":"2013","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23293331","citation_count":94,"is_preprint":false},{"pmid":"21726809","id":"PMC_21726809","title":"SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver.","date":"2011","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/21726809","citation_count":93,"is_preprint":false},{"pmid":"16458039","id":"PMC_16458039","title":"HRPT2 gene alterations in ossifying fibroma of the jaws.","date":"2006","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16458039","citation_count":84,"is_preprint":false},{"pmid":"15956079","id":"PMC_15956079","title":"HRPT2 mutational analysis of typical sporadic parathyroid adenomas.","date":"2005","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15956079","citation_count":83,"is_preprint":false},{"pmid":"16487440","id":"PMC_16487440","title":"Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours.","date":"2006","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16487440","citation_count":82,"is_preprint":false},{"pmid":"17639063","id":"PMC_17639063","title":"Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.","date":"2007","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17639063","citation_count":80,"is_preprint":false},{"pmid":"22187299","id":"PMC_22187299","title":"Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism.","date":"2012","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22187299","citation_count":77,"is_preprint":false},{"pmid":"18987311","id":"PMC_18987311","title":"The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18987311","citation_count":75,"is_preprint":false},{"pmid":"18212049","id":"PMC_18212049","title":"Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult mice.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18212049","citation_count":75,"is_preprint":false},{"pmid":"29324469","id":"PMC_29324469","title":"Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.","date":"2019","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29324469","citation_count":74,"is_preprint":false},{"pmid":"29040582","id":"PMC_29040582","title":"CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism.","date":"2017","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29040582","citation_count":74,"is_preprint":false},{"pmid":"22021426","id":"PMC_22021426","title":"The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22021426","citation_count":72,"is_preprint":false},{"pmid":"16728578","id":"PMC_16728578","title":"Loss of parafibromin expression in a subset of parathyroid adenomas.","date":"2006","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16728578","citation_count":70,"is_preprint":false},{"pmid":"17555500","id":"PMC_17555500","title":"Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17555500","citation_count":69,"is_preprint":false},{"pmid":"24145611","id":"PMC_24145611","title":"CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.","date":"2013","source":"Endocrine connections","url":"https://pubmed.ncbi.nlm.nih.gov/24145611","citation_count":68,"is_preprint":false},{"pmid":"16720667","id":"PMC_16720667","title":"Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance.","date":"2006","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16720667","citation_count":68,"is_preprint":false},{"pmid":"19906718","id":"PMC_19906718","title":"The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression.","date":"2009","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/19906718","citation_count":66,"is_preprint":false},{"pmid":"16989776","id":"PMC_16989776","title":"Parafibromin inhibits cancer cell growth and causes G1 phase arrest.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16989776","citation_count":64,"is_preprint":false},{"pmid":"16964291","id":"PMC_16964291","title":"Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16964291","citation_count":63,"is_preprint":false},{"pmid":"19522828","id":"PMC_19522828","title":"Parafibromin--functional insights.","date":"2009","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19522828","citation_count":60,"is_preprint":false},{"pmid":"22987117","id":"PMC_22987117","title":"CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.","date":"2012","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/22987117","citation_count":60,"is_preprint":false},{"pmid":"16995822","id":"PMC_16995822","title":"Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation.","date":"2006","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/16995822","citation_count":58,"is_preprint":false},{"pmid":"15070940","id":"PMC_15070940","title":"Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder mutation of the HRPT2 gene.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15070940","citation_count":53,"is_preprint":false},{"pmid":"20473645","id":"PMC_20473645","title":"Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.","date":"2010","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20473645","citation_count":52,"is_preprint":false},{"pmid":"22318720","id":"PMC_22318720","title":"Cdc73 subunit of Paf1 complex contains C-terminal Ras-like domain that promotes association of Paf1 complex with chromatin.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22318720","citation_count":51,"is_preprint":false},{"pmid":"17314275","id":"PMC_17314275","title":"Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function.","date":"2007","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/17314275","citation_count":49,"is_preprint":false},{"pmid":"18755853","id":"PMC_18755853","title":"Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism.","date":"2008","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18755853","citation_count":48,"is_preprint":false},{"pmid":"16116486","id":"PMC_16116486","title":"Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16116486","citation_count":48,"is_preprint":false},{"pmid":"18436011","id":"PMC_18436011","title":"Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations.","date":"2008","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/18436011","citation_count":47,"is_preprint":false},{"pmid":"16448924","id":"PMC_16448924","title":"Dental findings in a family with hyperparathyroidism-jaw tumor syndrome and a novel HRPT2 gene mutation.","date":"2005","source":"Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/16448924","citation_count":46,"is_preprint":false},{"pmid":"27650679","id":"PMC_27650679","title":"Dephosphorylated parafibromin is a transcriptional coactivator of the Wnt/Hedgehog/Notch pathways.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27650679","citation_count":44,"is_preprint":false},{"pmid":"23029104","id":"PMC_23029104","title":"Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23029104","citation_count":42,"is_preprint":false},{"pmid":"19368795","id":"PMC_19368795","title":"The role of Parafibromin/Hyrax as a nuclear Gli/Ci-interacting protein in Hedgehog target gene control.","date":"2009","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/19368795","citation_count":41,"is_preprint":false},{"pmid":"21717519","id":"PMC_21717519","title":"Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.","date":"2011","source":"Head & neck","url":"https://pubmed.ncbi.nlm.nih.gov/21717519","citation_count":41,"is_preprint":false},{"pmid":"15613436","id":"PMC_15613436","title":"A Novel IVS2-1G>A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroidism-jaw tumor syndrome.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15613436","citation_count":40,"is_preprint":false},{"pmid":"24823466","id":"PMC_24823466","title":"CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24823466","citation_count":39,"is_preprint":false},{"pmid":"20363855","id":"PMC_20363855","title":"PLANT HOMOLOGOUS TO PARAFIBROMIN is a component of the PAF1 complex and assists in regulating expression of genes within H3K27ME3-enriched chromatin.","date":"2010","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20363855","citation_count":39,"is_preprint":false},{"pmid":"17130827","id":"PMC_17130827","title":"Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17130827","citation_count":39,"is_preprint":false},{"pmid":"30227954","id":"PMC_30227954","title":"Transcriptional Co-activator Functions of YAP and TAZ Are Inversely Regulated by Tyrosine Phosphorylation Status of Parafibromin.","date":"2018","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/30227954","citation_count":39,"is_preprint":false},{"pmid":"32590342","id":"PMC_32590342","title":"Genotype of CDC73 germline mutation determines risk of parathyroid cancer.","date":"2020","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32590342","citation_count":36,"is_preprint":false},{"pmid":"30923346","id":"PMC_30923346","title":"Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.","date":"2019","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/30923346","citation_count":36,"is_preprint":false},{"pmid":"21837707","id":"PMC_21837707","title":"Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family.","date":"2011","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21837707","citation_count":35,"is_preprint":false},{"pmid":"16061557","id":"PMC_16061557","title":"Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism.","date":"2005","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16061557","citation_count":35,"is_preprint":false},{"pmid":"20026646","id":"PMC_20026646","title":"CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.","date":"2010","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20026646","citation_count":32,"is_preprint":false},{"pmid":"21221636","id":"PMC_21221636","title":"Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.","date":"2011","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21221636","citation_count":32,"is_preprint":false},{"pmid":"21790700","id":"PMC_21790700","title":"Identification of the first germline HRPT2 whole-gene deletion in a patient with primary hyperparathyroidism.","date":"2012","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21790700","citation_count":32,"is_preprint":false},{"pmid":"27462432","id":"PMC_27462432","title":"A genome-wide IR-induced RAD51 foci RNAi screen identifies CDC73 involved in chromatin remodeling for DNA repair.","date":"2015","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27462432","citation_count":32,"is_preprint":false},{"pmid":"27490759","id":"PMC_27490759","title":"Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.","date":"2017","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/27490759","citation_count":30,"is_preprint":false},{"pmid":"22932087","id":"PMC_22932087","title":"Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.","date":"2012","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/22932087","citation_count":30,"is_preprint":false},{"pmid":"32863766","id":"PMC_32863766","title":"Circ_0000140 restrains the proliferation, metastasis and glycolysis metabolism of oral squamous cell carcinoma through upregulating CDC73 via sponging miR-182-5p.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/32863766","citation_count":30,"is_preprint":false},{"pmid":"21652691","id":"PMC_21652691","title":"CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum.","date":"2011","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21652691","citation_count":30,"is_preprint":false},{"pmid":"18217513","id":"PMC_18217513","title":"Aberrant methylation of the HRPT2 gene in parathyroid carcinoma.","date":"2007","source":"The Annals of otology, rhinology, and laryngology","url":"https://pubmed.ncbi.nlm.nih.gov/18217513","citation_count":29,"is_preprint":false},{"pmid":"19908240","id":"PMC_19908240","title":"The tumor suppressor parafibromin is required for posttranscriptional processing of histone mRNA.","date":"2010","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/19908240","citation_count":29,"is_preprint":false},{"pmid":"18687124","id":"PMC_18687124","title":"The parafibromin tumor suppressor protein interacts with actin-binding proteins actinin-2 and actinin-3.","date":"2008","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18687124","citation_count":28,"is_preprint":false},{"pmid":"17639062","id":"PMC_17639062","title":"Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation.","date":"2007","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17639062","citation_count":28,"is_preprint":false},{"pmid":"25388829","id":"PMC_25388829","title":"Cytoplasmic parafibromin/hCdc73 targets and destabilizes p53 mRNA to control p53-mediated apoptosis.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25388829","citation_count":27,"is_preprint":false},{"pmid":"24257751","id":"PMC_24257751","title":"Transcriptional repression of tumor suppressor CDC73, encoding an RNA polymerase II interactor, by Wilms tumor 1 protein (WT1) promotes cell proliferation: implication for cancer therapeutics.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24257751","citation_count":27,"is_preprint":false},{"pmid":"20304979","id":"PMC_20304979","title":"Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome.","date":"2010","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20304979","citation_count":27,"is_preprint":false},{"pmid":"17404568","id":"PMC_17404568","title":"Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17404568","citation_count":27,"is_preprint":false},{"pmid":"24842573","id":"PMC_24842573","title":"Characterization of a new CDC73 missense mutation that impairs Parafibromin expression and nucleolar localization.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24842573","citation_count":26,"is_preprint":false},{"pmid":"21324824","id":"PMC_21324824","title":"Familial hyperparathyroidism due to a germline mutation of the CDC73 gene: implications for management and age-appropriate testing of relatives at risk.","date":"2011","source":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","url":"https://pubmed.ncbi.nlm.nih.gov/21324824","citation_count":25,"is_preprint":false},{"pmid":"17118068","id":"PMC_17118068","title":"Immunohistochemical assessment of parafibromin in mouse and human tissues.","date":"2006","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/17118068","citation_count":25,"is_preprint":false},{"pmid":"36928138","id":"PMC_36928138","title":"Spt6 directly interacts with Cdc73 and is required for Paf1 complex occupancy at active genes in Saccharomyces cerevisiae.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/36928138","citation_count":24,"is_preprint":false},{"pmid":"19474519","id":"PMC_19474519","title":"Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition.","date":"2009","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19474519","citation_count":23,"is_preprint":false},{"pmid":"16001331","id":"PMC_16001331","title":"HRPT2, a tumor suppressor gene for hyperparathyroidism-jaw tumor syndrome.","date":"2005","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/16001331","citation_count":23,"is_preprint":false},{"pmid":"24716902","id":"PMC_24716902","title":"Familial isolated primary hyperparathyroidism/hyperparathyroidism-jaw tumour syndrome caused by germline gross deletion or point mutations of CDC73 gene in Chinese.","date":"2014","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24716902","citation_count":22,"is_preprint":false},{"pmid":"21197463","id":"PMC_21197463","title":"Parafibromin as a diagnostic instrument for parathyroid carcinoma-lone ranger or part of the posse?","date":"2010","source":"International journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21197463","citation_count":21,"is_preprint":false},{"pmid":"30452964","id":"PMC_30452964","title":"CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors.","date":"2018","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/30452964","citation_count":20,"is_preprint":false},{"pmid":"35551175","id":"PMC_35551175","title":"UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35551175","citation_count":20,"is_preprint":false},{"pmid":"27658992","id":"PMC_27658992","title":"CDC73 gene mutations in sporadic ossifying fibroma of the jaws.","date":"2016","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27658992","citation_count":20,"is_preprint":false},{"pmid":"26232434","id":"PMC_26232434","title":"Parafibromin Is a Component of IFN-γ-Triggered Signaling Pathways That Facilitates JAK1/2-Mediated Tyrosine Phosphorylation of STAT1.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26232434","citation_count":20,"is_preprint":false},{"pmid":"27544721","id":"PMC_27544721","title":"A germline mutation of HRPT2/CDC73 (70 G>T) in an adolescent female with parathyroid carcinoma: first case report and a review of the literature.","date":"2016","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/27544721","citation_count":19,"is_preprint":false},{"pmid":"23453027","id":"PMC_23453027","title":"Assessing the contribution of HRPT2 to the pathogenesis of jaw fibrous dysplasia, ossifying fibroma, and osteosarcoma.","date":"2013","source":"Oral surgery, oral medicine, oral pathology and oral radiology","url":"https://pubmed.ncbi.nlm.nih.gov/23453027","citation_count":19,"is_preprint":false},{"pmid":"29142233","id":"PMC_29142233","title":"Crystal structure of the N-terminal domain of human CDC73 and its implications for the hyperparathyroidism-jaw tumor (HPT-JT) syndrome.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29142233","citation_count":19,"is_preprint":false},{"pmid":"26742426","id":"PMC_26742426","title":"Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26742426","citation_count":19,"is_preprint":false},{"pmid":"23029479","id":"PMC_23029479","title":"Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23029479","citation_count":18,"is_preprint":false},{"pmid":"18063086","id":"PMC_18063086","title":"Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism.","date":"2007","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/18063086","citation_count":17,"is_preprint":false},{"pmid":"21360064","id":"PMC_21360064","title":"Identification of de novo germline mutations in the HRPT2 gene in two apparently sporadic cases with challenging parathyroid tumor diagnoses.","date":"2011","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21360064","citation_count":17,"is_preprint":false},{"pmid":"29320491","id":"PMC_29320491","title":"Cdc73 suppresses genome instability by mediating telomere homeostasis.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29320491","citation_count":16,"is_preprint":false},{"pmid":"19092296","id":"PMC_19092296","title":"Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.","date":"2008","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19092296","citation_count":16,"is_preprint":false},{"pmid":"26675091","id":"PMC_26675091","title":"The Role of Parafibromin, Galectin-3, HBME-1, 
and Ki-67 in the Differential Diagnosis of Parathyroid Tumors.","date":"2015","source":"Oman medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/26675091","citation_count":16,"is_preprint":false},{"pmid":"21732217","id":"PMC_21732217","title":"Novel nonsense CDC73 mutations in Chinese patients with parathyroid tumors.","date":"2011","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21732217","citation_count":16,"is_preprint":false},{"pmid":"35654240","id":"PMC_35654240","title":"Diagnostic significance of parafibromin expression in parathyroid carcinoma.","date":"2022","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35654240","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51720,"output_tokens":8512,"usd":0.14142,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18188,"output_tokens":5086,"usd":0.109045,"stage2_stop_reason":"end_turn"},"total_usd":0.250465,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"Parafibromin (CDC73) is a component of a human PAF1 complex that includes homologs of Leo1, Paf1, and Ctr9, and associates with non-phosphorylated and Ser2/Ser5-phosphorylated forms of the RNA polymerase II large subunit. Immunofluorescence confirmed nuclear localization. Cotransfection data suggested parafibromin can interact with a histone methyltransferase complex that methylates histone H3 on lysine 4. Some tumor-derived mutant forms of parafibromin lack association with hPaf1 complex members and the histone methyltransferase complex.\",\n      \"method\": \"Protein purification, mass spectrometry identification of associated proteins, co-immunoprecipitation, immunofluorescence, cotransfection assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal purification and Co-IP with multiple orthogonal methods; replicated by independent lab (PMID:15923622)\",\n      \"pmids\": [\"15632063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Parafibromin physically interacts with human orthologs of yeast Paf1 complex components (PAF1, LEO1, CTR9) involved in transcription elongation and 3' end processing, and associates with Ser5- and Ser2-phosphorylated forms of RNA polymerase II large subunit. These interactions depend on a C-terminal domain of parafibromin deleted in ~80% of clinically relevant mutations. RNAi-induced downregulation of parafibromin promotes entry into S phase.\",\n      \"method\": \"Co-immunoprecipitation, RNAi knockdown, cell cycle analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, domain mapping, functional KD phenotype; independently replicated (PMID:15632063)\",\n      \"pmids\": [\"15923622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Drosophila Hyrax and its human ortholog parafibromin, components of the PAF1 complex, are required for nuclear transduction of the Wnt/Wg signal and bind directly to the C-terminal region of beta-catenin/Armadillo. The transactivation potential of Parafibromin/Hyrax depends on recruitment of Pygopus to beta-catenin/Armadillo, establishing a molecular mechanism in which the nuclear Wnt signaling complex directly engages the PAF1 complex to control transcriptional initiation and elongation by RNA Pol II.\",\n      \"method\": \"Genetic epistasis in Drosophila, direct binding assay (pulldown), transcriptional reporter assays, RNAi\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic epistasis combined with direct binding and transcriptional assays; landmark study with multiple orthogonal methods\",\n      \"pmids\": [\"16630820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Parafibromin overexpression (wild-type but not Leu64Pro missense mutant) inhibits cell proliferation and blocks expression of cyclin D1. Subcellular fractionation and confocal microscopy demonstrated parafibromin expression in both cytoplasmic and nuclear compartments of normal parathyroid gland.\",\n      \"method\": \"Transient overexpression, proliferation assay, cyclin D1 expression analysis, subcellular fractionation, laser confocal microscopy\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — clean overexpression with mutant control and defined readout, single lab\",\n      \"pmids\": [\"15580289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Parafibromin has a functional monopartite nuclear localization signal (NLS) at residues 136-139 (KKXR motif), identified by systematic deletion/mutation of predicted NLS sequences; mutation of this NLS abolishes nuclear localization. Over 60% of all parafibromin mutations lead to loss of this NLS.\",\n      \"method\": \"Site-directed mutagenesis, GFP-tagged constructs, confocal fluorescence microscopy, Western blot of nuclear/cytoplasmic fractions in COS-7 and HEK293 cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with multiple NLS variants and direct localization readout; consistent with independent NLS mapping study (PMID:16116486)\",\n      \"pmids\": [\"16964291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Parafibromin contains a functional bipartite nuclear localization signal (NLS) at residues 125-139 (KRAADEVLAEAKKPR). The C-terminal arm of this bipartite NLS plays the primary role in nuclear localization. Specific HRPT2 mutations that truncate parafibromin upstream of or within this NLS disrupt nuclear localization.\",\n      \"method\": \"EGFP-tagged wild-type and mutant parafibromin expression, confocal microscopy\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with mutagenesis, single lab\",\n      \"pmids\": [\"16116486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Nuclear localization of parafibromin enhances its proapoptotic function. NLS-mutant parafibromin is significantly impaired in association with endogenous Paf1 and Leo1. Overexpression of wild-type but not NLS-mutant parafibromin induces apoptosis. RNAi knockdown of endogenous parafibromin inhibits basal apoptosis and apoptosis resulting from DNA damage (camptothecin treatment).\",\n      \"method\": \"Site-directed mutagenesis, NLS mutation, co-immunoprecipitation, RNAi, apoptosis assays\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (mutagenesis, Co-IP, RNAi) in single lab\",\n      \"pmids\": [\"17314275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Parafibromin tumor suppressor protein inhibits cell proliferation and represses the c-myc proto-oncogene. RNAi knockdown of parafibromin or Paf1 stimulates cell proliferation and increases c-myc protein levels via both c-myc protein stabilization and activation of the c-myc promoter. Chromatin immunoprecipitation demonstrates occupancy of the c-myc promoter by parafibromin and other PAF1 complex subunits. Knockdown of c-myc blocks the proliferative effect of parafibromin RNAi.\",\n      \"method\": \"RNAi, cell proliferation assay, Western blot, chromatin immunoprecipitation (ChIP), epistasis by double knockdown\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (RNAi, ChIP, epistasis) in single lab establishing direct promoter occupancy and pathway placement\",\n      \"pmids\": [\"18987311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Parafibromin interacts with the histone methyltransferase SUV39H1 through its central region (residues 128-227) and functions as a transcriptional repressor. Parafibromin associates with the promoter and coding regions of cyclin D1 and is required for recruitment of SUV39H1 and induction of H3 K9 methylation (but not H3 K4 methylation) at the cyclin D1 locus, leading to repression.\",\n      \"method\": \"Co-immunoprecipitation, deletion mapping, ChIP, RNAi\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with domain mapping, ChIP, and RNAi epistasis in single lab\",\n      \"pmids\": [\"19906718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Cdc73/parafibromin physically associates with the cleavage and polyadenylation specificity factor (CPSF) and cleavage stimulation factor (CstF) complexes. Immunodepletion of Cdc73-CPSF-CstF complex abolishes 3' mRNA processing in vitro. CDC73 siRNA depletion results in decreased INTS6 mRNA and decreased association of CPSF and CstF subunits with the INTS6 locus.\",\n      \"method\": \"Co-immunoprecipitation, in vitro mRNA processing assay with immunodepletion, microarray analysis, ChIP\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro reconstitution/immunodepletion assay plus ChIP, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"19136632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SHP2 tyrosine phosphatase dephosphorylates parafibromin/Cdc73 on tyrosine residues. Upon dephosphorylation by SHP2, parafibromin acquires the ability to stably bind beta-catenin. The parafibromin/beta-catenin interaction overrides parafibromin/SUV39H1-mediated transrepression and induces expression of Wnt target genes including cyclin D1 and c-myc. Thus SHP2 governs the switch between parafibromin's tumor-suppressive and oncogenic functions.\",\n      \"method\": \"In vitro phosphatase assay, co-immunoprecipitation, reporter gene assays, phosphorylation-state mapping\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro phosphatase assay plus Co-IP and functional reporter assays demonstrating mechanistic switch; multiple orthogonal methods\",\n      \"pmids\": [\"21726809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CDC73 interacts with ring finger proteins RNF20 and RNF40 (which form the E3 ubiquitin ligase for H2B-K120 monoubiquitination), identified by yeast two-hybrid. RNF20 and RNF40 bind to discrete but closely located residues on CDC73. Loss of nuclear CDC73 (by siRNA or tumor mutations) significantly reduces monoubiquitinated H2B-K120. H3-K4me3 was not changed by CDC73 loss, indicating these modifications are not always tightly linked.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, RNAi knockdown, analysis of H2B-K120 monoubiquitination by Western blot, immunohistochemistry in CDC73-mutant tumors\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid confirmed by Co-IP, with functional histone modification readout in vitro and in vivo tumor specimens\",\n      \"pmids\": [\"22021426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Parafibromin (in the PAF complex) directly regulates genes involved in cell growth and survival including H19, Igf1, Igf2, Igfbp4, Hmga1, Hmga2, and Hmgcs2, as demonstrated by cDNA microarray, RT-PCR, and ChIP in parafibromin-null mouse embryonic fibroblasts. Hrpt2-/- mice are embryonic lethal by E6.5 and conditional deletion in adults causes cachexia and death within 20 days. Hrpt2-/- MEFs undergo apoptosis.\",\n      \"method\": \"Conventional and conditional knockout mice, MEF culture, cDNA microarray, ChIP, RT-PCR, apoptosis assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple genetic KO models plus ChIP and transcriptomics establishing direct gene targets; rigorous in vivo and in vitro validation\",\n      \"pmids\": [\"18212049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Parafibromin regulates 3' processing of replication-dependent histone mRNA. Downregulation of parafibromin by RNAi or tumor-associated mutations leads to uncleaved histone mRNA with polyadenylated tails, revealing a posttranscriptional role for parafibromin.\",\n      \"method\": \"RNAi knockdown, in vivo mutation analysis, histone mRNA 3' processing assay\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional in vitro and in vivo RNAi studies with specific mRNA processing readout, single lab\",\n      \"pmids\": [\"19908240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Parafibromin interacts with muscle alpha-actinins (actinin-2 and actinin-3) but not non-muscle alpha-actinins (actinin-1 and actinin-4) through its N-terminal region. Parafibromin can bundle/cross-link actin filaments in actin sedimentation assays. In differentiated myotubes, parafibromin co-localizes with actinins in the cytoplasmic compartment, whereas in undifferentiated myoblasts it is predominantly nuclear.\",\n      \"method\": \"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, actin sedimentation assay, confocal microscopy\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid confirmed by GST pulldown and Co-IP, functional actin bundling assay, localization by microscopy; single lab\",\n      \"pmids\": [\"18687124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Parafibromin inhibits cancer cell colony formation and proliferation and causes G1 phase cell cycle arrest when overexpressed. HPT-JT syndrome-derived mutations in HRPT2 behave in a dominant-negative manner by abolishing the ability of parafibromin to suppress cell proliferation.\",\n      \"method\": \"Colony formation assay, cell proliferation assay, cell cycle analysis (flow cytometry), dominant-negative overexpression of mutant constructs\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — overexpression with multiple mutants and defined cell cycle readout, single lab\",\n      \"pmids\": [\"16989776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Parafibromin/Hyrax directly binds Region 1 (the Su(fu) interaction domain) in the N-terminus of all three Gli proteins and Ci in Drosophila, forming complexes with Gli1, Gli2, and Gli3. RNAi knockdown of Hyrax impairs Hedgehog pathway activity in Drosophila cells. RNAi knockdown of Parafibromin in mammalian cells diminishes transcriptional activity of Gli1 and Gli2.\",\n      \"method\": \"Co-immunoprecipitation, RNAi in Drosophila cells and mammalian cells, Hh reporter assay, genetic overexpression in vivo\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional RNAi in two model systems, single lab\",\n      \"pmids\": [\"19368795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The Cdc73 subunit of the yeast Paf1 complex contains a C-terminal Ras-like domain (C-domain). The crystal structure of this domain reveals similarity to the Ras family of small GTPases with a large flat conserved surface. Deletion of the C-domain causes elongation defects and reduced chromatin association for multiple Paf1 complex subunits without loss of complex integrity. Simultaneous mutation of the C-domain and Rtf1 causes loss of H3K36 trimethylation.\",\n      \"method\": \"Crystal structure determination, deletion analysis, yeast genetics, chromatin immunoprecipitation\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure combined with genetic functional validation and ChIP; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"22318720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cytoplasmic parafibromin/hCdc73 targets and destabilizes p53 mRNA to control p53-mediated apoptosis. hCdc73 associates with mature p53 mRNA in the cytoplasm and facilitates its degradation by physically interacting with eEF1Bγ and hSki8; these interactions are required for binding and destabilizing p53 mRNA. A cancer-derived hCdc73(K34Q) mutant showed enhanced association with p53 mRNA, resulting in reduced p53 expression and enhanced cell proliferation.\",\n      \"method\": \"RNA immunoprecipitation, co-immunoprecipitation, mRNA stability assay, RNAi, overexpression of mutant constructs\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-IP and Co-IP with functional mutant analysis, single lab\",\n      \"pmids\": [\"25388829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CDC73/Parafibromin is required for homologous recombination repair of ionizing radiation-induced DNA damage. CDC73 interacts with components of the SCF/Cullin and INO80/NuA4 chromatin-remodeling complexes to promote histone ubiquitination at sites of DNA damage, facilitating local chromatin decondensation for DNA repair. This function is related to but independent of its role in transcriptional elongation.\",\n      \"method\": \"Genome-wide siRNA screen with RAD51 foci readout, validation by independent siRNAs, recombination repair activity assay, RPA foci formation assay, co-immunoprecipitation\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide screen with secondary validation assays and Co-IP, single lab\",\n      \"pmids\": [\"27462432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Dephosphorylated parafibromin competitively interacts with both beta-catenin and Gli1, potentiating Wnt and Hedgehog target gene transactivation in a mutually exclusive manner. Parafibromin also binds the Notch intracellular domain (NICD), enabling concerted activation of Wnt- and Notch-target genes. Tyrosine dephosphorylation by SHP2 phosphatase potentiates, while tyrosine phosphorylation by PTK6 kinase attenuates, the transcriptional platform function of parafibromin. Acute loss of parafibromin in mice disorganizes the normal epithelial architecture of the intestine.\",\n      \"method\": \"Co-immunoprecipitation, reporter assays, competitive binding assay, conditional knockout mice, intestinal phenotype analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple binding assays, reporter assays, and in vivo genetic model with defined phenotype in single rigorous study\",\n      \"pmids\": [\"27650679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"YAP and TAZ transcriptional co-activator functions are inversely regulated by the tyrosine phosphorylation status of parafibromin. TAZ and Wnt effector beta-catenin interact cooperatively with tyrosine-dephosphorylated parafibromin, synergistically stimulating co-activator functions. YAP is selectively activated through binding with tyrosine-phosphorylated parafibromin, which does not interact with beta-catenin. Thus YAP and TAZ exert redundant and non-redundant functions through mutually exclusive interaction with parafibromin regulated by kinase/phosphatase balance.\",\n      \"method\": \"Co-immunoprecipitation, reporter assays, phosphorylation-state analysis, mutant overexpression\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple Co-IPs and reporter assays establishing mechanistic switch, single lab\",\n      \"pmids\": [\"30227954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Parafibromin is a component of IFN-γ-triggered signaling pathways. Parafibromin interacts with JAK1 and JAK2, promotes JAK1-JAK2 and JAK1/2-STAT1 interactions, and promotes tyrosine phosphorylation of STAT1 at Tyr701 after IFN-γ stimulation. Overexpression of parafibromin enhanced IFN-γ-triggered STAT1 phosphorylation and downstream gene expression; knockdown had opposite effects.\",\n      \"method\": \"Co-immunoprecipitation, overexpression, RNAi knockdown, STAT1 phosphorylation assay, antiviral response assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with functional overexpression and knockdown readout, single lab\",\n      \"pmids\": [\"26232434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"UBR5 E3 ubiquitin ligase targets CDC73 for proteasomal degradation by polyubiquitination at Lys243, Lys247, and Lys257. This ubiquitination depends on the non-phosphorylated state of CDC73 at Ser465. CDC73 degradation by UBR5 regulates beta-catenin and E-cadherin expression, tumor cell apoptosis, and CD8+ T cell infiltration in triple-negative breast cancer.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, mutagenesis of ubiquitin acceptor sites and phosphorylation site, in vitro degradation assay\",\n      \"journal\": \"Cell death and disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination mapping with site mutagenesis and functional readout, single lab\",\n      \"pmids\": [\"35551175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of the human CDC73 N-terminal domain (residues 1-111) was determined at 1.02 Å resolution, revealing a novel protein fold with an extended hydrophobic groove. Most pathogenic HPT-JT-associated missense mutations are located in the region encoding CDC73-NTD and disrupt the folding of the hydrophobic core, while others (e.g., K34Q) reduce thermostability.\",\n      \"method\": \"Limited proteolysis, X-ray crystallography, biochemical stability assays, mutant analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure at high resolution with biochemical validation of missense mutations; single lab\",\n      \"pmids\": [\"29142233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The L95P missense mutant parafibromin is markedly deficient in nucleolar localization (disrupting a putative nucleolar localization signal immediately upstream of L95P), while retaining ability to assemble with endogenous PAF1 complex components by co-immunoprecipitation. Transfection of L95P parafibromin enhances cell cycle progression and cell survival, acting as a dominant-negative inhibitor of endogenous parafibromin.\",\n      \"method\": \"Subcellular localization by confocal microscopy, co-immunoprecipitation, cell cycle and cell survival assays with dominant-negative mutant\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — direct localization and Co-IP with functional dominant-negative readout, single lab\",\n      \"pmids\": [\"20304979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LEOPARD syndrome-associated SHP2 mutants (Y279C, T468M, Q506P, Q510E) exhibit substantially reduced phosphatase activity toward tyrosine-phosphorylated parafibromin compared to wild-type SHP2, as demonstrated in a direct in vitro phosphatase assay using parafibromin as substrate. Each LS-associated mutant displayed a differential degree of decrease in phosphatase activity.\",\n      \"method\": \"In vitro phosphatase assay with tyrosine-phosphorylated parafibromin as substrate\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro assay with multiple mutants, single lab, single method\",\n      \"pmids\": [\"26742426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In S. cerevisiae, Cdc73 directly interacts with two components of the RNA Pol II elongation complex: the elongation factor Spt6 and the largest subunit of Pol II, both interactions requiring the tandem SH2 domain of Spt6. Rapid depletion of Spt6 dissociates Paf1 from chromatin and alters Paf1C-dependent histone modifications genome-wide. Cdc73 and Spt6 can interact in vitro.\",\n      \"method\": \"Site-specific protein cross-linking in yeast, in vitro binding assay, rapid depletion/ChIP, genome-wide histone modification analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vivo cross-linking, in vitro binding, and genome-wide ChIP with rapid depletion; multiple orthogonal methods\",\n      \"pmids\": [\"36928138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In S. cerevisiae, Cdc73 suppresses genome instability by mediating telomere homeostasis. Loss of Cdc73 increases gross chromosomal rearrangement (GCR) rates. A central 105 amino acid region of Cdc73 is necessary and sufficient for suppressing GCR defects; this region mediates binding of Cdc73 to the Paf1 complex through Ctr9 and is required for nuclear localization. Synergistic increases in GCRs occur when cdc73Δ is combined with tel1Δ or yku80Δ, and telomere length defects are enhanced.\",\n      \"method\": \"GCR rate assay, genome sequencing of GCRs, deletion mapping of Cdc73, telomere length analysis, genetic epistasis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis, functional domain mapping, and telomere analysis; multiple orthogonal methods in yeast model\",\n      \"pmids\": [\"29320491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MiR-155 negatively regulates CDC73 expression at the post-transcriptional level by targeting CDC73 mRNA. Ectopic expression of miR-155 in HEK293 cells reduced CDC73 levels, enhanced cell viability, and decreased apoptosis. Delivery of miR-155 antagomir to KB cells restored CDC73 levels, decreased cell viability, and increased apoptosis. Co-transfection of miR-155 with CDC73 (without 3'-UTR) abrogated the pro-oncogenic effect of miR-155.\",\n      \"method\": \"MiR-155 overexpression and antagomir delivery, Western blot for CDC73, cell viability and apoptosis assays, 3'-UTR-dependent expression analysis, xenograft tumor model\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — gain/loss-of-function with epistasis rescue, in vitro and in vivo readout; single lab\",\n      \"pmids\": [\"23166327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"WT1 (Wilms tumor 1 protein) transcriptionally represses CDC73 by binding to the CDC73 promoter. ChIP and EMSA demonstrated direct WT1 binding to the CDC73 promoter. Overexpression of WT1 decreased CDC73 levels and promoted proliferation of OSCC cells. Exogenous CDC73 attenuated the pro-tumorigenic activity of WT1.\",\n      \"method\": \"ChIP, EMSA, overexpression, knockdown, proliferation/apoptosis assays, 5-azacytidine treatment\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding demonstrated by ChIP and EMSA with functional epistasis, single lab\",\n      \"pmids\": [\"24257751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Disruption of the C-terminal domain (CTD) of parafibromin by germline CDC73 mutations is directly associated with predisposition to parathyroid carcinoma. High-impact mutations predicted to cause conformational disruption or loss of expression of parafibromin confer a 6.6-fold higher risk of parathyroid carcinoma compared to low-impact mutations. Structural analysis revealed a conserved surface structure in the CTD that is universally disrupted by carcinoma-associated mutations.\",\n      \"method\": \"Cohort analysis of mutation carriers with Kaplan-Meier analysis, structural modeling of CTD mutations\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Moderate — structural inference from mutation correlation; no direct functional experiment performed\",\n      \"pmids\": [\"32590342\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDC73/parafibromin is a nuclear tumor suppressor that functions as a core subunit of the RNA Polymerase II-associated PAF1 complex, where it facilitates transcription elongation, 3' mRNA processing (via association with CPSF/CstF), and histone modifications (H3K9me via SUV39H1 and H2B-K120 monoubiquitination via RNF20/RNF40); it represses oncogenes cyclin D1 and c-myc, while its transcriptional coactivator function—particularly activation of Wnt, Hedgehog, and Notch target genes through direct binding to beta-catenin, Gli proteins, and NICD—is governed by SHP2-mediated tyrosine dephosphorylation (activating) versus PTK6-mediated tyrosine phosphorylation (inhibiting), with UBR5-dependent proteasomal degradation providing an additional layer of regulation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CDC73/parafibromin is a nuclear tumor suppressor that functions as a core subunit of the human PAF1 complex (with PAF1, LEO1, and CTR9), coupling RNA polymerase II transcription elongation to histone modification and 3' mRNA processing [#0, #1, #9]. Within this complex it controls transcription of genes governing proliferation and survival: it represses the oncogenes cyclin D1 and c-myc, occupying their promoters and recruiting the histone methyltransferase SUV39H1 to deposit repressive H3K9 methylation at cyclin D1 [#7, #8], and it interacts with the RNF20/RNF40 E3 ligase to promote H2B-K120 monoubiquitination [#11]. CDC73 also acts as a transcriptional co-activator at developmental signaling pathways, binding directly to beta-catenin (Wnt), Gli proteins (Hedgehog), and the Notch intracellular domain to drive target-gene expression [#2, #16, #20]. This dual repressor/activator output is governed by a tyrosine phosphorylation switch: SHP2-mediated dephosphorylation enables stable beta-catenin binding and an oncogenic activating program, whereas PTK6 phosphorylation attenuates it, with the phospho-state also dictating selective engagement of TAZ versus YAP [#10, #20, #21]. Nuclear function depends on an N-terminal nuclear localization signal and the structured N- and C-terminal domains, regions disrupted by the majority of HPT-JT and parathyroid carcinoma-associated mutations [#4, #24, #31]. Beyond transcription, CDC73 contributes to homologous recombination DNA repair through SCF/Cullin and INO80/NuA4 complexes [#19] and exerts cytoplasmic post-transcriptional roles, including destabilization of p53 mRNA via eEF1Bgamma and hSki8 [#18]. Germline CDC73 mutations that disrupt the C-terminal domain predispose to parathyroid carcinoma [#31].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Establishing that parafibromin is a bona fide subunit of the RNA Pol II-associated PAF1 complex placed an uncharacterized tumor suppressor into a defined transcriptional machinery and showed tumor mutations disrupt this association.\",\n      \"evidence\": \"Protein purification, mass spectrometry, reciprocal Co-IP and immunofluorescence in human cells; replicated with domain mapping and RNAi cell-cycle assays\",\n      \"pmids\": [\"15632063\", \"15923622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PAF1 complex assembly is sufficient for tumor suppression not resolved\", \"Direct enzymatic activity of CDC73 within the complex undefined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identification of direct binding to beta-catenin/Armadillo defined parafibromin as a nuclear effector of Wnt signaling, recasting the PAF1 complex as a transcriptional platform engaged by developmental pathways.\",\n      \"evidence\": \"Drosophila genetic epistasis, direct pulldown, transcriptional reporter assays, RNAi\",\n      \"pmids\": [\"16630820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same protein both represses and activates Wnt targets not yet reconciled at this stage\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Mapping a functional nuclear localization signal explained why ~60% of clinical mutations cause mislocalization, linking subcellular targeting to loss of tumor-suppressor function.\",\n      \"evidence\": \"Site-directed mutagenesis of NLS variants, GFP/EGFP constructs, confocal microscopy and nuclear/cytoplasmic fractionation\",\n      \"pmids\": [\"16964291\", \"16116486\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Import receptor mediating NLS recognition not identified\", \"Monopartite versus bipartite NLS boundaries differ between studies\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Knockout mouse models and direct promoter occupancy studies established CDC73 as an essential gene that directly represses c-myc and regulates growth/survival genes, defining its anti-proliferative mechanism.\",\n      \"evidence\": \"Conventional and conditional knockout mice, MEF transcriptomics, ChIP, RT-PCR, plus RNAi/ChIP/epistasis at the c-myc locus\",\n      \"pmids\": [\"18212049\", \"18987311\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism distinguishing repressed versus activated targets not defined\", \"Embryonic lethality limits tissue-specific dissection\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linking CDC73 to SUV39H1-mediated H3K9 methylation and to CPSF/CstF-dependent 3' processing extended its mechanism from elongation to chromatin repression and mRNA maturation.\",\n      \"evidence\": \"Co-IP with deletion mapping, ChIP, RNAi, and in vitro mRNA processing assays with immunodepletion\",\n      \"pmids\": [\"19906718\", \"19136632\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether 3' processing and transcriptional roles are mechanistically separable unresolved\", \"Genome-wide scope of CPSF/CstF coupling not mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstration of direct Gli binding generalized parafibromin's co-activator role beyond Wnt to the Hedgehog pathway.\",\n      \"evidence\": \"Co-IP, RNAi in Drosophila and mammalian cells, Hedgehog reporter assays\",\n      \"pmids\": [\"19368795\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Competition between Gli and beta-catenin binding not yet examined at this stage\", \"Structural basis of Gli interaction undefined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Discovery of the SHP2 tyrosine dephosphorylation switch resolved the repressor/activator paradox, showing a single post-translational signal toggles parafibromin between tumor-suppressive and oncogenic outputs.\",\n      \"evidence\": \"In vitro phosphatase assay, Co-IP, reporter assays, phosphorylation-state mapping\",\n      \"pmids\": [\"21726809\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals controlling SHP2 activity toward parafibromin unidentified\", \"Specific phosphotyrosine residues and counteracting kinase not yet defined here\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of RNF20/RNF40 binding connected CDC73 to H2B-K120 monoubiquitination, adding a second histone-modification arm to its chromatin function.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, RNAi, H2B-K120ub Western blot, tumor immunohistochemistry\",\n      \"pmids\": [\"22021426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of H2B ubiquitination loss for specific target genes not delineated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Crystallization of the yeast Cdc73 C-terminal Ras-like domain provided structural rationale for its role in elongation and chromatin association and for the clustering of clinical mutations in this region.\",\n      \"evidence\": \"Crystal structure, deletion analysis, yeast genetics, ChIP\",\n      \"pmids\": [\"22318720\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the Ras-like surface binds a GTPase or other partner unknown\", \"No nucleotide-binding activity demonstrated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defining a cytoplasmic role in destabilizing p53 mRNA revealed a transcription-independent oncogenic function for CDC73 acting through RNA decay machinery.\",\n      \"evidence\": \"RNA-IP, Co-IP with eEF1Bgamma and hSki8, mRNA stability assays, RNAi, cancer mutant analysis\",\n      \"pmids\": [\"25388829\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; reciprocal validation of eEF1Bgamma/hSki8 RNA-decay complex limited\", \"Signal partitioning CDC73 between nucleus and cytoplasm unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"A genome-wide screen placed CDC73 in homologous recombination DNA repair, linking it to SCF/Cullin and INO80/NuA4 chromatin remodeling at damage sites independently of elongation.\",\n      \"evidence\": \"Genome-wide siRNA screen with RAD51 foci, recombination repair and RPA foci assays, Co-IP\",\n      \"pmids\": [\"27462432\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct enzymatic role at break sites not established\", \"Interaction with INO80/NuA4 not reciprocally mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showing competitive, mutually exclusive binding to beta-catenin, Gli1, and NICD, all tuned by SHP2/PTK6, established parafibromin as an integrating hub coordinating Wnt, Hedgehog, and Notch output, with in vivo intestinal phenotypes.\",\n      \"evidence\": \"Competitive binding and reporter assays, Co-IP, conditional knockout mice with intestinal phenotyping\",\n      \"pmids\": [\"27650679\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative rules governing pathway selection not defined\", \"Tissue-specific kinase/phosphatase balance not mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"High-resolution structure of the CDC73 N-terminal domain explained how HPT-JT missense mutations destabilize the protein, providing a structural basis for loss of function.\",\n      \"evidence\": \"Limited proteolysis, X-ray crystallography at 1.02 A, biochemical stability assays, mutant analysis\",\n      \"pmids\": [\"29142233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding partner engaged by the NTD hydrophobic groove not identified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extending the phospho-switch to YAP/TAZ and identifying the Spt6 elongation-factor contact (in yeast) further refined how phosphorylation state and elongation machinery shape parafibromin co-activator selectivity.\",\n      \"evidence\": \"Co-IP and reporter assays for YAP/TAZ; yeast site-specific cross-linking, in vitro binding, rapid depletion and genome-wide ChIP for Spt6\",\n      \"pmids\": [\"30227954\", \"36928138\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"YAP/TAZ findings single lab without in vivo confirmation\", \"Conservation of Spt6 contact in human PAF1 complex not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of UBR5-mediated, phospho-dependent polyubiquitination of CDC73 added a degradation layer controlling parafibromin levels and downstream beta-catenin/E-cadherin and immune phenotypes in breast cancer.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, mutagenesis of acceptor lysines and Ser465, in vitro degradation assay\",\n      \"pmids\": [\"35551175\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; physiological signals triggering UBR5 targeting unknown\", \"Interplay with SHP2/PTK6 phospho-switch not integrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the competing nuclear (PAF1 elongation, repression, co-activation, DNA repair) and cytoplasmic (mRNA destabilization, actin bundling) activities of parafibromin are coordinately regulated in a cell-type-specific manner, and which functions are most relevant to tumor suppression, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model integrating phospho-switch, ubiquitination, and localization control\", \"Functional ranking of nuclear versus cytoplasmic roles in carcinogenesis undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 7, 8, 16, 20]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [9, 18]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [8, 11]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 2, 20]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 4, 6]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [14, 18]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 7, 8]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [9, 13, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 16, 20, 21]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [8, 11]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [31]}\n    ],\n    \"complexes\": [\n      \"PAF1 complex\",\n      \"CPSF/CstF 3' processing complex\"\n    ],\n    \"partners\": [\n      \"PAF1\",\n      \"LEO1\",\n      \"CTR9\",\n      \"CTNNB1\",\n      \"SUV39H1\",\n      \"RNF20\",\n      \"PTPN11\",\n      \"PTK6\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}